FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...
Find MoreOral Mucositis (OM) refers to erythematous and ulcerative lesions of the oral mucosa observed in cancer patients under chemotherapy or radiation therapy. In its severe form, OM presents as confluent, deep ulcerations. Typical manifestations are atrophy, erythema, ulceration, and swelling of the mucosa. It appears fi...
Find MoreOral Mucositis is a commonly occurring, most debilitating complication of cancer chemotherapy and radiotherapy. It can be characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drugs and radiotherapy used in cancer treatment. Potential complications of oral mucositis include p...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.